Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 04, 2019 07:30 ET | Source: Aptose Biosciences, Inc.

Aptose Appoints Rafael Bejar, M.D., Ph.D., as Chief Medical Officer

SAN DIEGO and TORONTO, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the...
December 02, 2019 07:30 ET | Source: Aptose Biosciences, Inc.

Aptose to Present at 31st Annual Piper Jaffray Healthcare Conference

SAN DIEGO and TORONTO, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
November 07, 2019 07:30 ET | Source: Aptose Biosciences, Inc.

Aptose to Present at BIO-Europe Conference

SAN DIEGO and TORONTO, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
November 06, 2019 09:54 ET | Source: Aptose Biosciences, Inc.

Aptose to Present New CG-806 Data at the 2019 ASH Annual Meeting

– Company to Hold Event During ASH – – CG-806 Preclinical Abstracts Accepted for Presentation – SAN DIEGO and TORONTO, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”)...
November 05, 2019 16:02 ET | Source: Aptose Biosciences, Inc.

Aptose Reports Results for the Third Quarter Ended September 30, 2019

CG-806 Mutation Agnostic FLT3/BTK Inhibitor and APTO-253 MYC Inhibitor Safely Dose Escalate CLL Patient Treated with Second Dose Level of CG-806 Shows Evidence of Clinical Response Conference Call...
October 22, 2019 07:00 ET | Source: Aptose Biosciences, Inc.

Aptose To Release Third Quarter Ended September 30, 2019 Financial Results and Hold Conference Call on November 5, 2019

SAN DIEGO and TORONTO, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target the...
October 10, 2019 07:30 ET | Source: Aptose Biosciences, Inc.

Aptose to Participate at 5th International Conference on Acute Myeloid Leukemia of the European School of Haematology (ESH)

SAN DIEGO and TORONTO, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated...
September 16, 2019 07:30 ET | Source: Aptose Biosciences, Inc.

Aptose to Participate in Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies

SAN DIEGO and TORONTO, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated...
August 06, 2019 16:00 ET | Source: Aptose Biosciences, Inc.

Aptose Reports Results for the Second Quarter Ended June 30, 2019

─ APTO-253 Inhibits MYC in AML and MDS Patients in Phase 1 Clinical Trial ─ ─ First CLL Patient Dosed with CG-806 in Phase 1 Clinical Trial ─ Conference Call and Webcast at 5pm EDT Today ...
July 30, 2019 07:30 ET | Source: Aptose Biosciences, Inc.

Aptose Biosciences to Present at Canaccord Genuity 39th Annual Growth Conference

SAN DIEGO and TORONTO, July 30, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the...